Mercados españoles cerrados en 7 hrs 14 min

Heron Therapeutics, Inc. (HRTX)

NasdaqCM - NasdaqCM Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
5,11-0,26 (-4,84%)
Al cierre: 04:00PM EDT
5,00 -0,11 (-2,15%)
Después del cierre: 07:46PM EDT

Heron Therapeutics, Inc.

4242 Campus Point Court
Suite 200
San Diego, CA 92121
United States
858 251 4400
https://www.herontx.com

Sector(es)Healthcare
SectorBiotechnology
Empleados a tiempo completo302

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Dr. Barry D. Quart Pharm.D.Chairman & CEO1,1MN/A1957
Mr. John W. PoyhonenPres & Chief Commercial Officer722,35kN/A1960
Mr. David L. SzekeresExec. VP & COO710,66kN/A1974
Ms. Lisa PerazaVP & Chief Accounting Officer474,1kN/A1977
Ms. Kimberly J. ManhardExec. VP of Drug Devel. & Director739,8kN/A1960
Mr. Sean T. RistineSr. VP of HRN/AN/A1970
Dr. Thomas B. Ottoboni Ph.D.Chief Scientific Officer and Sr. VP of Pharmaceutical & Translational SciencesN/AN/A1959
Mr. Michael E. MathewsSr. VP of Acute CareN/AN/A1963
Dr. Chris M. StorgardChief Medical OfficerN/AN/A1966
Los importes son a partir de 31 de diciembre de 2021 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Gobierno corporativo

El ISS Governance QualityScore de Heron Therapeutics, Inc., a día 31 de julio de 2022, es 4. Las puntuaciones base son Auditoría: 4; Tablero: 6; Derechos de los accionistas: 1; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.